Literature DB >> 17122970

E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes.

E Czeslick1, A Struppert, A Simm, A Sablotzki.   

Abstract

OBJECTIVE AND
DESIGN: In this ex vivo laboratory study, we investigated the effects of E5564 (eritoran), a toll-like receptor 4-directed endotoxin antagonist, on intracellular expression of interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha in lipopolysaccharide (LPS)-stimulated human monocytes assessed by flow cytometry. MATERIAL AND
METHOD: Whole blood samples from 10 healthy volunteers (average age: 32 +/- 2 years) were pre-incubated with 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1 and 10 ng/ml E5564 for 45 min and after this stimulated with LPS (0.2 ng/ml), a dose we found to be the most effective for stimulation. Samples were incubated for 3 h at 37 degrees C and 5% CO(2). Intracellular expression of IL-6 and TNF-alpha was assessed by flow cytometry.
RESULTS: Our investigation showed that E5564 (0.03 ng/ml up to 10 ng/ml) caused a dose-dependent inhibitory effect on IL-6 and TNF-alpha production in LPS-stimulated human monocytes.
CONCLUSIONS: The results of this investigation led us to conclude that E5564 has a remarkable LPS inhibitory activity manifested via down-regulation of the intracellular generation of pro-inflammatory cytokines IL-6 and TNF-alpha in human monocytes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17122970     DOI: 10.1007/s00011-006-6057-3

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  20 in total

1.  Early immune senescence in HIV disease.

Authors:  Seema Desai; Alan Landay
Journal:  Curr HIV/AIDS Rep       Date:  2010-02       Impact factor: 5.071

Review 2.  Dysregulation of human Toll-like receptor function in aging.

Authors:  Albert C Shaw; Alexander Panda; Samit R Joshi; Feng Qian; Heather G Allore; Ruth R Montgomery
Journal:  Ageing Res Rev       Date:  2010-11-10       Impact factor: 10.895

3.  Toll-like receptors and opportunities for new sepsis therapeutics.

Authors:  John H Boyd
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

Review 4.  Targeting Toll-like receptors: emerging therapeutics?

Authors:  Elizabeth J Hennessy; Andrew E Parker; Luke A J O'Neill
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

Review 5.  Progress in the synthesis and biological evaluation of lipid A and its derivatives.

Authors:  Jian Gao; Zhongwu Guo
Journal:  Med Res Rev       Date:  2017-06-16       Impact factor: 12.944

Review 6.  TLRs, future potential therapeutic targets for RA.

Authors:  Hatem A Elshabrawy; Abdul E Essani; Zoltán Szekanecz; David A Fox; Shiva Shahrara
Journal:  Autoimmun Rev       Date:  2016-12-15       Impact factor: 9.754

7.  Neisseria meningitidis capsular polysaccharides induce inflammatory responses via TLR2 and TLR4-MD-2.

Authors:  Susu M Zughaier
Journal:  J Leukoc Biol       Date:  2010-12-29       Impact factor: 4.962

8.  Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling.

Authors:  Kerry-Ann Mcdonald; Hai Huang; Samer Tohme; Patricia Loughran; Kimberly Ferrero; Timothy Billiar; Allan Tsung
Journal:  Mol Med       Date:  2015-03-13       Impact factor: 6.354

Review 9.  Toll-like receptor 4 modulation as a strategy to treat sepsis.

Authors:  X Wittebole; D Castanares-Zapatero; P F Laterre
Journal:  Mediators Inflamm       Date:  2010-04-14       Impact factor: 4.711

10.  Upregulation of TLR2/4 expression in mononuclear cells in postoperative systemic inflammatory response syndrome after liver transplantation.

Authors:  Ziqing Hei; Xinjin Chi; Nan Cheng; Gangjian Luo; Shangrong Li
Journal:  Mediators Inflamm       Date:  2010-06-16       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.